BDTX Black Diamond Therapeutics
- 4.650
- -0.170-3.53%
- 4.540
- -0.110-2.37%
Black Diamond Therapeutics News
Reported Saturday, Black Diamond Therapeutics Showcased BDTX-1535 Clinical Data In Patients With Recurrent Glioblastoma At 2024 ASCO Annual Meeting
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatmentInitial d
Black Diamond Therapeutics: Phase 1 dose-escalation trial results of bdtx-1535 in GBM patients show good safety and tolerability
Black Diamond Therapeutics: Phase 1 dose-escalation trial results of bdtx-1535 in GBM patients show good safety and tolerability
Express News | Black Diamond Therapeutics: Results From Phase 1 Dose Escalation Trial of Bdtx-1535 in GBM Patients Demonstrated Favorable Safety and Tolerability
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients With Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) today presented additional data from the Phase 1 dose escalation trial of BDTX-1535 in patients with recurrent glioblastoma (GBM), and initial data from a phase 0/1 "trigger" ("window of opportunity") investigator-sponsored trial at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
PDF Version CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target fami
Black Diamond Theraptcs Is Maintained at Buy by HC Wainwright & Co.
Black Diamond Theraptcs Is Maintained at Buy by HC Wainwright & Co.
Black Diamond Theraptcs Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Black Diamond Theraptcs Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
HC Wainwright & Co. : Maintaining the Black Diamond Therapeutic (BDTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
HC Wainwright & Co. : Maintaining the Black Diamond Therapeutic (BDTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $11
HC Wainwright & Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and lowers the price target from $12 to $11.
Buy Rating Affirmed for Black Diamond Therapeutics Amid Strong Financials and Promising Clinical Trials
Black Diamond Therapeutics Expects Cash & Equivalents Of $115.2M As Of March-End To Be Sufficient To Fund Operations Into Q3 Of 2025
Black Diamond Therapeutics Expects Cash & Equivalents Of $115.2M As Of March-End To Be Sufficient To Fund Operations Into Q3 Of 2025
Black Diamond Therapeutic Q1 2024 GAAP EPS $(0.35) Beats $(0.44) Estimate
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.44) by 20.45 percent.
Black Diamond Theraptcs 1Q Loss/Shr 35c >BDTX
Black Diamond Theraptcs 1Q Loss/Shr 35c >BDTX
Press Release: Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024
Black Diamond Therapeutics | 10-Q: Quarterly report
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PDF Version Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; ini
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
PDF Version CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target fa
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
Garry Menzel Joins GHO Capital as Operating Partner
Garry Menzel joins GHO Capital as Operating Partner Former CEO of TCR2 Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering
Press Release: Black Diamond Therapeutics Announces Changes to Board of Directors
Black Diamond Therapeutics Announces Changes to Board of Directors CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology comp
Analysis
Price Target
No Data
